Financial Advocates Investment Management Cuts Position in Gossamer Bio, Inc. (NASDAQ:GOSS)

Financial Advocates Investment Management cut its stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 12.4% in the 3rd quarter, Holdings Channel.com reports. The fund owned 93,550 shares of the company’s stock after selling 13,300 shares during the period. Financial Advocates Investment Management’s holdings in Gossamer Bio were worth $92,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. NEA Management Company LLC lifted its stake in Gossamer Bio by 14.2% during the 2nd quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock valued at $16,300,000 after acquiring an additional 2,255,025 shares during the period. Monaco Asset Management SAM increased its holdings in shares of Gossamer Bio by 390.3% in the second quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company’s stock worth $2,456,000 after purchasing an additional 2,170,104 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Gossamer Bio by 170.8% during the 2nd quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock worth $3,002,000 after acquiring an additional 2,103,766 shares in the last quarter. Renaissance Technologies LLC lifted its position in Gossamer Bio by 204.7% during the second quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company’s stock valued at $1,844,000 after purchasing an additional 1,375,000 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in Gossamer Bio by 51.6% in the first quarter. Acadian Asset Management LLC now owns 2,736,385 shares of the company’s stock worth $3,227,000 after acquiring an additional 931,248 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on GOSS. Wedbush reaffirmed an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research note on Tuesday, September 17th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Trading Up 1.4 %

GOSS stock opened at $0.89 on Tuesday. The company has a current ratio of 8.21, a quick ratio of 8.21 and a debt-to-equity ratio of 2.42. Gossamer Bio, Inc. has a 12-month low of $0.49 and a 12-month high of $1.60. The stock has a market cap of $200.51 million, a price-to-earnings ratio of -2.27 and a beta of 1.96. The business’s 50-day moving average is $0.94 and its 200 day moving average is $0.86.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Monday, August 12th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The business had revenue of $95.84 million during the quarter, compared to analyst estimates of $160.00 million. On average, sell-side analysts anticipate that Gossamer Bio, Inc. will post -0.33 EPS for the current fiscal year.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.